Celyad Announces Positive New Data from its CAR-T NKR-2 Phase I Trial at 2016 ASH Annual Meeting

Celyad Announces Positive New Data from its CAR-T NKR-2 Phase I Trial at 2016 ASH Annual Meeting

Celyad announces the approval to initiate its NKR-2 CAR-T Clinical Trial in Belgium

Celyad announces the approval to initiate its NKR-2 CAR-T Clinical Trial in Belgium

Celyad’s NKR-2 Phase I safety trial delivers encouraging results to be presented at ASH 2016

Celyad’s NKR-2 Phase I safety trial delivers encouraging results to be presented at ASH 2016

Celyad responds to misleading statements on its patent relating to allogeneic human primary T-Cells that are engineered to be TCR-deficient and express a CAR

Celyad responds to misleading statements on its patent relating to allogeneic human primary T-Cells that are engineered to be TCR-deficient and express a CAR

Celyad completes the NKR-2 Phase I trial with successful safety follow-up of the fourth dose level

Celyad completes the NKR-2 Phase I trial with successful safety follow-up of the fourth dose level

Celyad successfully completes safety follow-up of the first patient at the fourth dose level in the NKR-2 Phase I trial

Celyad successfully completes safety follow-up of the first patient at the fourth dose level in the NKR-2 Phase I trial

Celyad treats first patient in the fourth dose level of its NKR-2 trial

Celyad treats first patient in the fourth dose level of its NKR-2 trial

Celyad successfully completes safety follow-up of the third dose level of its NKR-2 Trial

Celyad successfully completes safety follow-up of the third dose level of its NKR-2 Trial

Celyad Announces Oral Presentation on NKR-2 T Cells Manufacturing for a First-in-Human Clinical Trial in AML and Multiple Myeloma

Celyad Announces Oral Presentation on NKR-2 T Cells Manufacturing for a First-in-Human Clinical Trial in AML and Multiple Myeloma

Celyad successfully completes safety follow-up of the first patient in the third dose level of its NKR-2 Trial

Celyad successfully completes safety follow-up of the first patient in the third dose level of its NKR-2 Trial

Celyad receives the first US patent covering a method of producing Allogeneic TCR-deficient CAR T-cells

Celyad receives the first US patent covering a method of producing Allogeneic TCR-deficient CAR T-cells

Celyad successfully completes safety follow-up of the second dose level of patients in its NKR-2 Trial and enrolls first patient in the third dose level

Celyad successfully completes safety follow-up of the second dose level of patients in its NKR-2 Trial and enrolls first patient in the third dose level